Welcome to the fourth volume of *Melanoma Management* and a look back at 2016

Sebastian Dennis-Beron*

“As 2016 comes to a close, we look forward to a series of exciting developments planned for 2017. These developments include, but are not limited to, engaging with a wider audience within the cancer management community, revising our aims and scopes, and potentially featuring new and innovative article types...”

We are delighted to welcome all our readers to the fourth volume of *Melanoma Management*. The year 2016 was a ground breaking year in melanoma research and another sensational year for the journal, as we continued to receive high-quality manuscripts from contributors across the field of melanoma research.

We would like to take this opportunity to thank our valued editorial board, contributors and readers for the support we have received since our inception, but particularly over the last 12 months. The editorial teams very much look forward to seeing the journal further mature and develop over the course of 2017.

Emerging Sources Citation Index indexing

I am delighted to announce that this year we became indexed on the Thompson indexing service, Emerging Sources Citation Index. Not only does this give an indication of the quality of the journal, as being indexed on Emerging Sources Citation Index will increase the journal's visibility and coverage, but it is also a key component toward becoming indexed on the Science Citation Index.

Content highlights of 2016

• Top articles

At the time of writing (November 2016), our most-read article was a piece by Hegde,

Mukherji and Grant-Kels from the University of Connecticut Health Center Cutaneous Oncology and Melanoma Center (CT, USA), that discussed the role of age in metastatic melanoma immunotherapy [1]. The article probed into the limitations faced with providing elderly melanoma patients with immunotherapeutics, such as treatment efficacy, toxicities and potential issues with immune senescence.

A highlight of 2016 was an interview with M Herlyn from the Wistar Institute (PA, USA) that coincided with Herlyn's 40th year in melanoma research [2]. The interview looked back at some of Herlyn's career achievements, discussed his views on the current state of the field and the strides it has made in recent times, and finally gave his expert opinion on where melanoma research is going and the direction it should aim to advance in.

Also highly popular was an Editorial by Vardabasso and Bernstein from the Icahn School of Medicine at Mount Sinai (NY, USA), which asked, “Can histone proteins promote the growth of melanoma?” [3]. The article discussed the role of epigenomic regulation in melanoma and how aberrant expression of histone variants can disrupt the cellular epigenetic balance and ultimately contributing to progression of the malignancy.

One of our most-read articles was by P de Keizer from the Erasmus University Medical

KEYWORDS

- immunotherapy
- management • melanoma
- skin cancer • viral therapy

“In 2016, we solidified our partnership with the online platform Oncology Central, which we established at the end of 2015.”

*Future Science Group, Unitec House, 2 Albert Place, London N31QB, UK; s.dennis-beron@futuremedicine.com

“It is interesting to note how the journals readership has progressed over the last year; from the demographics we can see that our content is having a global impact...”

Center (Rotterdam, The Netherlands) discussing whether Pin1–FOXO1 inhibitors are a suitable therapeutic for metastatic melanoma [4].

Another of our top articles was by Bhatt *et al.* from the Montefiore Medical Center (NY, USA) and the Icahn School of Medicine at Mount Sinai (NY, USA) [5]. The article discussed whether an increased number of moles correlates to a higher risk of melanoma, probing into the correlation between melanocytic nevi and the cancer.

The following articles achieved the highest Altmetric scores in the journal to date:

- Our highest scoring article was the aforementioned editorial by Bhatt *et al.* “Does an increased number of moles correlate to a higher risk of melanoma?” [5];
- “Electrochemotherapy: a good idea in recurrent basal cell carcinoma treatment” by Ruggeri *et al.* [6];
- “Intratumoral talimogene laherparepvec therapy in melanoma” by Senior Editor, Kim [7].

• Special focus issue

The final issue of our third volume (Volume 3, Issue 4) was a special issue focusing on the pivotal role immunotherapies have assumed in the melanoma field. The issue highlights the latest advancements in melanoma immunotherapy with respect to cancer vaccines and viral-based therapies, with a range of articles discussing the developments in various vaccine candidates for melanoma as well as expert opinions and experiences with such vaccines both in clinical trials and in standard practice – the issue was guest edited by renowned expert in the field of cancer vaccines, RO Dillman [8].

Figure 1. Readership demographics per continent for *Melanoma Management* in 2016.

Oncology Central

In 2016, we solidified our partnership with the online platform Oncology Central [9], which we established at the end of 2015. Oncology Central is a free online resource that is designed exclusively for its medical professionals with an interest in oncology, aiming to deliver high-quality and relevant content in an accessible and innovative way. Through Oncology Central, we endeavor to keep our increasing audience of approximately 5200 professionals up to date with the latest developments in cancer management and research with free access to the latest oncology news, opinion, peer-reviewed journal articles and more exclusive content.

The partnership means that as well as featuring our content on the site, Oncology Central members have free access to all content published from across the Oncology Management journals published by Future Medicine (*Breast Cancer Management, CNS Oncology, Colorectal Cancer, Hepatic Oncology, International Journal of Endocrine Oncology, International Journal of Hematologic Oncology, Lung Cancer Management and Melanoma Management*).

If you would like to be a member of *Oncology Central* yourself, you will receive free access to timely content published in Oncology Central-partnered journals. Please feel free to contact us via email: oncology.management@futuremedicine.com.

.Readership demographics

It is interesting to note how the journals readership has progressed over the last year; from the demographics we can see that our content is having a global impact, with our content being read somewhat evenly between North America (34%), Europe (25%) and Eurasia (36%) (Figure 1). Where we have continued our strong following in both North America and Europe, it is exciting to see our Eurasian readership grow from across Australia, China and Taiwan. I look forward to seeing our readership continue to grow within the cancer management community, as we continue expanding our journal to this global audience.

Conclusion

As 2016 comes to a close, we look forward to a series of exciting developments planned for 2017. These developments include, but are not limited to, engaging with a wider audience within the cancer management community, revising our aims and scopes, and potentially featuring new

and innovative article types, which we hope could be of great value to the field. We appreciate all feedback from the oncology community regarding the direction of our content, such as ‘hot topics’ in the field and trends that you feel we should cover as a management-focused journal.

We welcome unsolicited article proposals, and would be delighted to hear from you, particularly if you have any original research or case reports aimed specifically at the management of melanoma, which we are actively aiming to feature in the journal.

Do follow the journal on twitter (@fsgmmt), for the latest updates from the journal and the latest new from across the field.

We greatly look forward to collaborating with you all over the next year and hope *Melanoma Management* continues to fulfill its role in the cancer management community and grow and develop as a journal.

Financial & competing interests disclosure

S Dennis-Beron is an employee of Future Medicine Ltd. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

References

- 1 Hegde UP, Mukherji B, Grant-Kels Jane M. Emerging immune therapy of metastatic melanoma in the older patient: does age really matter? *Melanoma Manag.* 3(1), 9–12 (2016).
- 2 Herlyn M. 40 years in melanoma research: an interview with Meenhard Herlyn about his career in research and the outlook for the field. *Melanoma Manag.* 3(3), 165–169 (2016).
- 3 Vardabasso C, Bernstein E. Can histone proteins promote the growth of melanoma? *Melanoma Manag.* 3(1), 1–4 (2016).
- 4 de Keizer PL. Pin1–FOXO1 inhibitors: a potential therapeutic for metastatic melanoma? *Melanoma Manag.* 3(3), 161–164 (2016).
- 5 Bhatt B, Nabatian A, Kriegel D, Khorasani H. Does an increased number of moles correlate to a higher risk of melanoma? *Melanoma Manag.* 3(2), 85–87 (2016).
- 6 Ruggeri R, Maurichi A, Tinti MC. Electrochemotherapy: a good idea in recurrent basal cell carcinoma treatment. *Melanoma Manag.* 2(1), 27–31 (2015).
- 7 Kim K. Intratumoral talimogene laherparepvec therapy in melanoma. *Melanoma Manag.* 2(4), 297–231 (2015).
- 8 Dillman RO, Dennis-Beron S. Melanoma vaccines and viral-based immunotherapies: a special focus issue from Melanoma Management. *Melanoma Manag.* 3(4), 245–246 (2016).
- 9 Oncology Central website. www.oncology-central.com